| Prev Close | 560.98 |
| Day Low/High | 558.12 / 574.19 |
| 52 Wk Low/High | 271.37 / 583.54 |
| Avg Volume | 1.38M |
Regeneron Pharmaceuticals Inc. (REGN)
569.91
NASDAQ : Health Technology
| Exchange | NASDAQ |
| Shares Outstanding | 110.67M |
| Market Cap | 63.12B |
| EPS | 19.40 |
| P/E Ratio | 28.19 |
| Div & Yield | N.A. (N.A) |
Latest News
Regeneron Pharmaceuticals Could Trade Sideways Before Renewed Gains
Use available weakness to go long or add to longs.
Jim Cramer: This Opening Is the Beginning of the End of the Healthcare Recession
What's really driving the market, what's making the Nasdaq roar? Tech and science, that's what.
Buffett's Great Airline Escape, Tech Leadership, ECB Wiggle Room
Don't just follow the herd, time your exits and entrances well -- even if it is a big player like Warren Buffett that is leading the charge.
Jim Cramer: Reopening Is Necessary, but Based on Little More Than Hope
It's imperative that people get back to work, so we have this great compromise -- let's see how it might play out.
Real Money Post-Industrial Average Feels the Pain, But Continues to Outperform
For March and the first quarter, the RMPIA takes less of a hit than major indexes.
Jim Cramer: Here Are the Quarter's Winners, Losers
The five best performing and worst performing stocks in the S&P 500 in the previous quarter pretty much tells the tale of the tape, so here goes.
Jim Cramer: Here's the Science Behind Our Rally
While Johnson & Johnson and other pharma cos. give us hope, here's my wish list to keep the nation safe and the economy ready to go again.
Sanofi's Charts Show Upside Potential Amid Its Covid-19 Work
The drug and vaccine maker possibly could see its shares double according to a key chart.
Jim Cramer: The Rescue Bill and a Fed Dive-Bombing Policy Ignited All Sectors
I think our scientists, our medical minds, are working on an atomic bomb that can nuke Covid before it invades us.
Failed Rallies, Semiconductors Rising and the Fed's Big Guns
The Fed has attacked developing problems in real-time -- and as China shows signs of life, the semi stocks are benefitting.
The Fed's Big Bazooka, Covid-19 Treatments, Market Breather
Amid dramatically rising jobless claims, the Fed continues to fire big bullets, the Senate is pushing its economic support package and Gilead and Regeneron have made progress on coronavirus treatments.
These Are the Times We Live In
Here again is my approach and my three stock groups: 'rebound', 'revenue' and 'virus'.
Regeneron Pharmaceuticals Could Be a Bright Spot in a Sea of Declines
We looked at the charts of REGN yesterday but with things (read: stock prices) changing so fast it wouldn't hurt to look again.
The Magic Mice of Regeneron
I am pretty well covered in my 'virus group'. I could definitely see bringing a few shares of REGN on board the next time the algorithms include that name in a broad selloff. Not before.
Regeneron Pharmaceuticals Presents Bullish Charts Amid Covid-19 Work
The biopharma giant's work on a coronavirus antibody treatment is helping move its shares in a different direction than the market has taken.
5 Leading Biotechs in Search of a Coronavirus Vaccine
The race is on. The prize could be countless lives saved and perhaps billions of dollars in revenue.
This Stock Is Standing Up to the Correction Like Few Others
Biotech name has bolted higher with some amazing relative strength.
Real Money Post Industrial Average Holds Own Amid Covid-19 Selloff
Amid a flood of corporate warnings over the coronavirus, all the major stock market indexes finished last month down 6.4% to 10.1%.
Jim Cramer: Rate Cut No Cure for Coronavirus
But don't throw up your arms yet -- here are names that could be golden opportunities.
Regeneron's Pullback Amid Market Weakness Could Lead to Buying Opportunity
The biopharma giant could fall further, so wait for a candlestick reversal pattern before going long.
Regeneron Pharmaceuticals Could Surprise on the Upside With Its Quant Buy Signal
Are the technical and quantitative approaches on the same page?
RMPIA Lags in November, but Trounces S&P 500 for Quarter, Year So Far
Now, many Real Money Post Industrial Average stocks should see a boost from the holiday splurge by shoppers.
Real Money Post Industrial Average Exits October on Top
The RMPIA's 3.8% jump even beat the Nasdaq Composite Index's 3.7% October climb.
Real Money Post-Industrial Average Continues to Outpace Major Indices
RMPIA is up 20.9% in the first nine months of 2019.
Otezla Price Under Microscope -- but Look Closely and It Checks Out
Sure, Celgene, in its tie-up with Bristol-Myers Squibb, had to sell to meet merger requirements, but look at the future pay off for Amgen.
